NCT02946775 (CABSYNC) is a clinical trial in Community-Acquired Infections, sponsored by University of Nebraska.

Who is sponsoring NCT02946775?

NCT02946775 is sponsored by University of Nebraska.

What condition does NCT02946775 study?

NCT02946775 studies Community-Acquired Infections.

Is NCT02946775 still recruiting?

NCT02946775 is currently completed. Last updated 29 September 2023.

Last reviewed 2023-09-29 · How we verify

NCT02946775: CABSYNC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Community Acquired Bacteremic Syndromes in Young Nigerian Children

Completed Last updated 29 September 2023

What this trial tests

trial in Community-Acquired Infections in 29,146 participants. Completed in 1 July 2018.

Timeline

13 September 2012

Primary endpoint
1 July 2018

1 July 2018

Quick facts

Lead sponsor	University of Nebraska
Status	Completed
Study type	OBSERVATIONAL
Enrollment	29,146
Start date	13 September 2012
Primary completion	1 July 2018
Estimated completion	1 July 2018
Sites	1 location across Nigeria

Conditions studied

Community-Acquired Infections — all drugs for Community-Acquired Infections →

Sponsor

University of Nebraska

Who can join

Adults 1 Minute to 14, any sex, with Community-Acquired Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To define the etiologic agents of community acquired bacteremic syndromes (defined as septicemia, bacteremia, pneumonia and/or meningitis) in a malaria endemic setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Nebraska trials

Trials by the same sponsor.

NCT07507006 — Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance · NA · not yet recruiting
NCT07517705 — MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma · NA · not yet recruiting
NCT07506993 — Inflammation in Clear Aligners With and Without Attachments · not yet recruiting
NCT07207850 — Parents Helping Parents for Youth Vaping Cessation · NA · not yet recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02946775 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nebraska
Last refreshed: 29 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02946775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing